Arovella Therapeutics (ALA) Q3 2026 TU earnings summary

Executive summary

• IND for ALA-101 accepted by the US FDA, enabling first-in-human clinical trials for CD19-positive non-Hodgkin's lymphoma and leukemia.

• TGA confirmed ALA-101 Phase 1 trial can proceed in Australia via the CTN scheme, streamlining regulatory approval.

• Preclinical data showed potent and durable activity of CLDN18.2 CAR-iNKT cells, with enhanced killing using IL-12-TM armouring.

• Board changes included the retirement of Dr Elizabeth Stoner and Mr Gary Phillips as Non-Executive Directors.

Financial highlights

• Cash and cash equivalents at 31 March 2026 were $16.6 million.

• Net cash outflows from operating activities for the quarter were $2.8 million.

• Research and development and staff costs accounted for 84.5% of operating outflows.

• Received $0.28 million post-quarter as part of the FY2025 R&D Tax Incentive.

Outlook and guidance

• Phase 1 clinical trial for ALA-101 expected to commence in Q3 CY26, with funding secured to generate preliminary safety and efficacy data.

• Continued progress on solid tumour program targeting CLDN18.2, with integration of IL-12-TM armouring.

• Ongoing review of new technologies for potential acquisition to enhance the CAR-iNKT platform.